EVALUATION OF DANAZOL AS AN ORAL CONTRACEPTIVE

N H Lauersen, K H Wilson
In: InPharma · 1977 · vol. 110(1) , pp. 10 · doi:10.1007/bf03289420 · PMID:141634 · W2416144331
article OA: closed CC0 ⤵ 10 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

This newsletter article evaluates the potential of danazol as an oral contraceptive.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-12 · read from full text ⓘ

This brief 1977 newsletter article evaluates danazol when used as an oral contraceptive, focusing on reported performance of the drug in that context. It is presented as a short Inpharma Weekly item with limited methodological detail in the available text, and access restrictions indicate the full content is not shown in the provided excerpt, limiting appraisal of study design and outcomes. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The effect of Danazol as an oral contraceptive in doses of 50, 100, and 200 mg daily for 6 months was studied in 3 groups of 10 women. Both 50 and 100 mg Danazol daily were well tolerated, but one pregnancy occurred among the women receiving 50 mg daily, and 2 pregnancies occurred in women receiving 100 mg daily. There were no pregnancies in women taking 200 mg Danazol daily; however, the side effects were frequent and 5 of the 10 patients withdrew from the study prior to 6 months of therapy. Six patients in this study were followed intensively with blood hormone analysis, vaginal cytology, and pathologic evaluation, and these findings are detailed.
Full text 808 characters · extracted from oa-doi-fallback · click to expand
Rights and permissions About this article Cite this article EVALUATION OF DANAZOL AS AN ORAL CONTRACEPTIVE. Inpharma Wkly. 110, 10 (1977). https://doi.org/10.1007/BF03289420 Published: Issue date: DOI: https://doi.org/10.1007/BF03289420 - Newsletter Article - Published: - Volume 110, page 10 (1977) - Cite this article - 2 Accesses This is a preview of subscription content, log in via an institution to check access. EVALUATION OF DANAZOL AS AN ORAL CONTRACEPTIVE. Inpharma Wkly. 110, 10 (1977). https://doi.org/10.1007/BF03289420 Published: Issue date: DOI: https://doi.org/10.1007/BF03289420 Anyone you share the following link with will be able to read this content: Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (10)

SciLite annotations

chemicals 3
danazol danazol danazol

Source provenance

openalex
last seen: 2026-05-10T10:30:37.675330+00:00
scilite
last seen: 2026-05-18T04:26:01.642840+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK